Ibogaminalog

Ibogaminalog (developmental code name DM-506) is a non-selective and non-psychedelic serotonin receptor modulator of the ibogalog group related to the iboga alkaloid ibogamine but with a simplified chemical structure. It was first described in the 1960s but was subsequently further studied and reported on in the 2020s.

Ibogaminalog is known to act as an agonist of serotonin receptors, including of the serotonin 5-HT_2A receptor (K_i = 17–11,190 nM; EC₅₀Tooltip half-maximal effective concentration = 2.9–34 nM; E_maxTooltip maximal efficacy = 33–76%), the serotonin 5-HT_2B receptor (K_i = 16.5–63,780 nM; EC₅₀ = 2.9–33 nM; E_max = 68–69%), and the serotonin 5-HT₆ receptor (EC₅₀ = 2.9 nM; E_max = 96%), and as an inverse agonist of the serotonin 5-HT₇ receptor (I_maxTooltip maximal inhibition = 14%).

It is a weak to very weak monoamine reuptake inhibitor, including of serotonin, norepinephrine, and dopamine (IC₅₀Tooltip half-maximal inhibitory concentration = 3,100 nM, 9,500 nM, and 70,000 nM, respectively), whereas it is not a significant monoamine oxidase inhibitor (MAOI) of MAO-A or MAO-B. The drug also acts weakly as a negative allosteric modulator of the α₇ and α₉α₁₀ nicotinic acetylcholine receptors.

Ibogaminalog does not produce the head-twitch response, a behavioral proxy of psychedelic effects, in rodents, and hence may be non-hallucinogenic in humans. On the other hand, it has been found to produce sedative, antidepressant-like, anxiolytic-like, antiaddictive-like, and analgesic-like effects in rodents.